Novo Nordisk is investing about $225M in a new 80,729-square-foot facility in Kalundborg, Denmark, and is expected to be fully operational in 2020. The plant will produce active pharmaceutical ingredients for NovoSeven and future products for treating haemophilia, the company said.
The investment is estimated to create 100 new production and engineering jobs in Kalundborg, where Novo Nordisk currently employs more than 2,800 people.
"The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees," said Henrik Wulff, executive vice president, product supply, Novo Nordisk.